Peringatan Keamanan

LD50 (mouse) = 390-1005 mg/kg, LD50 (rat) = 150-190 mg/kg. Side effects include nausea, vomiting and myelosuppression. Toxic effects include central nervous system toxicity (confusion, hallucinations) and urotoxic effects (cystitis, blood in urine).

Ifosfamide

DB01181

small molecule approved

Deskripsi

Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.

Struktur Molekul 2D

Berat 261.086
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 7-15 hours. The elimination half-life increase appeared to be related to the increase in ifosfamide volume of distribution with age.
Volume Distribusi Ifosfamide volume of distribution (Vd) approximates the total body water volume, suggesting that distribution takes place with minimal tissue binding. Following intravenous administration of 1.5 g/m2 over 0.5 hour once daily for 5 days to 15 patients with neoplastic disease, the median Vd of ifosfamide was 0.64 L/kg on Day 1 and 0.72 L/kg on Day 5. When given to pediatric patients, the volume of distribution was 21±1.6 L/m^2.
Klirens (Clearance) * 2.4±0.33 L/h/m^2 [pediatric patients]

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Primarily hepatic. Ifosfamide is metabolized through two metabolic pathways: ring oxidation ("activation") to form the active metabolite, 4-hydroxy-ifosfamide and side-chain oxidation to form the inactive metabolites, 3-dechloro-ethylifosfamide or 2-dechloroethylifosfamide with liberation of the toxic metabolite, chloroacetaldehyde. Small quantities (nmol/mL) of ifosfamide mustard and 4-hydroxyifosfamide are detectable in human plasma. Metabolism of ifosfamide is required for the generation of the biologically active species and while metabolism is extensive, it is also quite variable among patients.

Rute Eliminasi

Ifosfamide is extensively metabolized in humans and the metabolic pathways appear to be saturated at high doses. After administration of doses of 5 g/m2 of 14C-labeled ifosfamide, from 70% to 86% of the dosed radioactivity was recovered in the urine, with about 61% of the dose excreted as parent compound. At doses of 1.6–2.4 g/m2 only 12% to 18% of the dose was excreted in the urine as unchanged drug within 72 hours.

Interaksi Makanan

3 Data
  • 1. Avoid alcohol. Ingesting alcohol may worsen nausea and vomiting caused by ifosfamide.
  • 2. Exercise caution with grapefruit products. Grapefruit inhibits the CYP3A4 metabolism of ifosfamide to its active metabolite, therefore reducing its efficacy.
  • 3. Exercise caution with St. John's Wort. Close monitoring is warranted as this herb induces the CYP3A4 metabolism of ifosfamide to its alkylating active metabolites, including, chloroacetaldehyde, a nephrotoxic and neurotoxic metabolite.

Interaksi Obat

1747 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Ifosfamide.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ifosfamide.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Ifosfamide.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Ifosfamide.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ifosfamide.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Ifosfamide.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Ifosfamide.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ifosfamide.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Ifosfamide.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ifosfamide.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ifosfamide.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Ifosfamide.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Ifosfamide.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Ifosfamide.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ifosfamide.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Ifosfamide.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ifosfamide.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Ifosfamide.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Ifosfamide.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ifosfamide.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ifosfamide.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Ifosfamide.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Ifosfamide.
Cladribine Ifosfamide may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Ifosfamide.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Ifosfamide.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Ifosfamide.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Ifosfamide.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Ifosfamide.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Ifosfamide.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Ifosfamide.
Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Ifosfamide.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Ifosfamide.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Ifosfamide.
Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Ifosfamide.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Ifosfamide.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Ifosfamide.
Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Ifosfamide.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Ifosfamide.
Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Ifosfamide.
Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Ifosfamide.
Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Ifosfamide.
Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Ifosfamide.
Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Ifosfamide.
Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Ifosfamide.
Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Ifosfamide.
Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Ifosfamide.
Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ifosfamide.
Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Ifosfamide.
Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Ifosfamide.
Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Ifosfamide.
Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Ifosfamide.
Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Ifosfamide.
Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Ifosfamide.
Azathioprine The risk or severity of adverse effects can be increased when Azathioprine is combined with Ifosfamide.
Hydroxyurea The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Ifosfamide.
Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ifosfamide.
Mercaptopurine The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Ifosfamide.
Thalidomide The metabolism of Ifosfamide can be increased when combined with Thalidomide.
Melphalan The risk or severity of adverse effects can be increased when Melphalan is combined with Ifosfamide.
Fludarabine The risk or severity of adverse effects can be increased when Fludarabine is combined with Ifosfamide.
Flucytosine The risk or severity of adverse effects can be increased when Flucytosine is combined with Ifosfamide.
Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Ifosfamide.
Arsenic trioxide The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Ifosfamide.
Idarubicin The risk or severity of adverse effects can be increased when Idarubicin is combined with Ifosfamide.
Estramustine The risk or severity of adverse effects can be increased when Ifosfamide is combined with Estramustine.
Lomustine The risk or severity of adverse effects can be increased when Ifosfamide is combined with Lomustine.
Eculizumab The risk or severity of adverse effects can be increased when Ifosfamide is combined with Eculizumab.
Decitabine The risk or severity of adverse effects can be increased when Ifosfamide is combined with Decitabine.
Nelarabine The risk or severity of adverse effects can be increased when Ifosfamide is combined with Nelarabine.
Stepronin The risk or severity of adverse effects can be increased when Ifosfamide is combined with Stepronin.
Hydroxychloroquine The risk or severity of adverse effects can be increased when Ifosfamide is combined with Hydroxychloroquine.
Castanospermine The risk or severity of adverse effects can be increased when Ifosfamide is combined with Castanospermine.
Vorinostat The risk or severity of adverse effects can be increased when Ifosfamide is combined with Vorinostat.
2-Methoxyethanol The risk or severity of adverse effects can be increased when Ifosfamide is combined with 2-Methoxyethanol.
Brequinar The risk or severity of adverse effects can be increased when Ifosfamide is combined with Brequinar.
Aldosterone The risk or severity of adverse effects can be increased when Ifosfamide is combined with Aldosterone.
Pirfenidone The risk or severity of adverse effects can be increased when Ifosfamide is combined with Pirfenidone.
Interferon alfa The risk or severity of adverse effects can be increased when Ifosfamide is combined with Interferon alfa.
Glatiramer The risk or severity of adverse effects can be increased when Ifosfamide is combined with Glatiramer.
Briakinumab The risk or severity of adverse effects can be increased when Ifosfamide is combined with Briakinumab.
Human interferon omega-1 The risk or severity of adverse effects can be increased when Ifosfamide is combined with Human interferon omega-1.
Mepolizumab The risk or severity of adverse effects can be increased when Ifosfamide is combined with Mepolizumab.
Abetimus The risk or severity of adverse effects can be increased when Ifosfamide is combined with Abetimus.
Belatacept The risk or severity of adverse effects can be increased when Ifosfamide is combined with Belatacept.
Bendamustine The risk or severity of adverse effects can be increased when Ifosfamide is combined with Bendamustine.
Pralatrexate The risk or severity of adverse effects can be increased when Ifosfamide is combined with Pralatrexate.
Wortmannin The risk or severity of adverse effects can be increased when Ifosfamide is combined with Wortmannin.
Eribulin The risk or severity of adverse effects can be increased when Ifosfamide is combined with Eribulin.
Belimumab The risk or severity of adverse effects can be increased when Ifosfamide is combined with Belimumab.
Teriflunomide The risk or severity of adverse effects can be increased when Ifosfamide is combined with Teriflunomide.
Carfilzomib The risk or severity of adverse effects can be increased when Ifosfamide is combined with Carfilzomib.
Dimethyl fumarate The risk or severity of adverse effects can be increased when Ifosfamide is combined with Dimethyl fumarate.
Obinutuzumab The risk or severity of adverse effects can be increased when Ifosfamide is combined with Obinutuzumab.
Vedolizumab The risk or severity of adverse effects can be increased when Ifosfamide is combined with Vedolizumab.
Blinatumomab The risk or severity of adverse effects can be increased when Ifosfamide is combined with Blinatumomab.
Dinutuximab The risk or severity of adverse effects can be increased when Ifosfamide is combined with Dinutuximab.
Vilanterol The risk or severity of adverse effects can be increased when Ifosfamide is combined with Vilanterol.
Tixocortol The risk or severity of adverse effects can be increased when Ifosfamide is combined with Tixocortol.
Peginterferon beta-1a The risk or severity of adverse effects can be increased when Ifosfamide is combined with Peginterferon beta-1a.

Target Protein

DNA
Nuclear receptor subfamily 1 group I member 2 NR1I2

Referensi & Sumber

Synthesis reference: U.S. Patent 3,732,340.
Artikel (PubMed)
  • PMID: 14586139
    Furlanut M, Franceschi L: Pharmacology of ifosfamide. Oncology. 2003;65 Suppl 2:2-6.
  • PMID: 9322882
    Fleming RA: An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy. 1997 Sep-Oct;17(5 Pt 2):146S-154S.
  • PMID: 8070218
    Wagner T: Ifosfamide clinical pharmacokinetics. Clin Pharmacokinet. 1994 Jun;26(6):439-56.
  • PMID: 1277221
    Allen LM, Creaven PJ, Nelson RL: Studies on the human pharmacokinetics of isophosphamide (NSC-109724). Cancer Treat Rep. 1976 Apr;60(4):451-8.
  • PMID: 3896483
    Brade WP, Herdrich K, Varini M: Ifosfamide--pharmacology, safety and therapeutic potential. Cancer Treat Rev. 1985 Mar;12(1):1-47.
  • PMID: 3286879
    Zalupski M, Baker LH: Ifosfamide. J Natl Cancer Inst. 1988 Jun 15;80(8):556-66.
  • PMID: 15827549
    Willits I, Price L, Parry A, Tilby MJ, Ford D, Cholerton S, Pearson AD, Boddy AV: Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Br J Cancer. 2005 May 9;92(9):1626-35.
  • PMID: 16702183
    Lokiec F: Ifosfamide: pharmacokinetic properties for central nervous system metastasis prevention. Ann Oncol. 2006 May;17 Suppl 4:iv33-6.
Menampilkan 8 dari 10 artikel.

Contoh Produk & Brand

Produk: 40 • International brands: 4
Produk
  • Ifex
    Injection, powder, for solution • 1 g/20mL • Intravenous • US • Approved
  • Ifex
    Injection, powder, for solution • 3 g/60mL • Intravenous • US • Approved
  • Ifex
    Injection, powder, for solution • 1 g/20mL • Intravenous • US • Approved
  • Ifex
    Injection, powder, for solution • 3 g/60mL • Intravenous • US • Approved
  • Ifex
    Powder, for solution • 3 g / vial • Intravenous • Canada • Approved
  • Ifex
    Powder, for solution • 1 g / vial • Intravenous • Canada • Approved
  • Ifex
    Injection, powder, for solution • 1 g/20mL • Intravenous • US • Approved
  • Ifex
    Injection, powder, for solution • 3 g/60mL • Intravenous • US • Approved
Menampilkan 8 dari 40 produk.
International Brands
  • Celofos — Celon
  • Cuantil — Teva
  • Holoxan — Baxter
  • Mitoxana — Baxter

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul